Pfizer's arthritis drug shows efficacy in late-stage trial

06/20/2010 | Reuters

Patients with rheumatoid arthritis demonstrated significant reduction in knee pain and improvement in physical function after receiving one of three doses of Pfizer's injectable biotech drug tanezumab during a late-stage trial. The medicine targets nerve growth factor, a protein associated with pain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX